2026 Q3 Portfolio Activity
In 2026 Q3, Squadron Capital Management LLC maintained a portfolio of 64 distinct positions. The most significant new addition was SILENCE THERAPEUTICS PLC, now representing 5.72% of the total fund value. They heavily accumulated shares in C4 THERAPEUTICS INC, increasing the position by 2229.7%. The fund also reduced its exposure to RELMADA THERAPEUTICS INC by 52.4%.
Position History
hover any row below to update
Loading…
Total Positions
64
Quarter
2026 Q3
Top Holding
KOD (10.0%)
Top 10 Concentration
56.6%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 64
Squadron Capital Management LLC Full Holdings List — 2026 Q3
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
KOD
KODIAK SCIENCES...
|
Healthcare | 9.99% | 6.05% |
#1
3
Prev: #4
|
6.5 |
—
|
-80,000 | -16.0% |
P
S
|
420,000 | $39,816,000 |
$46.80
+109.2%
|
2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
CCCC
C4 THERAPEUTICS...
|
Healthcare | 7.79% | 10.43% |
#2
Prev: #2
|
7.1 |
—
|
2,118,683 | 29.4% |
P
S
|
9,318,683 | $31,031,214 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 7.35% | 10.39% |
#3
Prev: #3
|
5.9 |
—
|
50,000 | 5.8% |
P
S
|
915,000 | $29,298,300 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
KOD
CALL
KODIAK SCIENCES...
|
CALL Option | 6.42% | — |
#4
Prev: #—
|
6.6 |
—
|
270,000 | — |
NEW
|
270,000 | $25,596,000 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SLN
SILENCE THERAPE...
|
Healthcare | 5.72% | — |
#5
Prev: #—
|
6.3 |
—
|
2,085,000 | — |
NEW
|
2,085,000 | $22,789,050 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ZNTL
ZENTALIS PHARMA...
|
Healthcare | 4.75% | 5.57% |
#6
Prev: #6
|
4.9 |
—
|
3,127,905 | 84.5% |
P
S
|
6,827,905 | $18,913,297 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
EWTX
EDGEWISE THERAP...
|
Healthcare | 4.33% | 3.66% |
#7
Prev: #7
|
4.2 |
—
|
135,000 | 46.6% |
P
S
|
425,000 | $17,255,000 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
RLAY
RELAY THERAPEUT...
|
Healthcare | 3.56% | 5.63% |
#8
3
Prev: #5
|
1.9 |
—
|
-185,000 | -19.1% |
P
S
|
785,000 | $14,169,250 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ORIC
ORIC PHARMACEUT...
|
Healthcare | 3.38% | — |
#9
Prev: #—
|
4.9 |
—
|
1,000,000 | — |
NEW
|
1,000,000 | $13,470,000 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
RLMD
RELMADA THERAPE...
|
Healthcare | 3.31% | 15.78% |
#10
9
Prev: #1
|
1.3 |
—
|
-3,850,000 | -52.4% |
P
S
|
3,500,000 | $13,195,000 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
DFTX
DEFINIUM THERAP...
|
Healthcare | 3.25% | 1.24% |
#11
14
Prev: #25
|
4.3 |
—
|
255,000 | 300.0% |
P
S
|
340,000 | $12,940,400 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
PHVS
PHARVARIS N V
|
Healthcare | 3.18% | — |
#12
Prev: #—
|
4.8 |
—
|
400,000 | — |
NEW
|
400,000 | $12,688,000 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ANL
ADLAI NORTYE GR...
|
Healthcare | 3.07% | 2.73% |
#13
3
Prev: #10
|
2.2 |
—
|
no change | no change |
P
S
|
764,876 | $12,238,016 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
VERA
VERA THERAPEUTI...
|
Healthcare | 2.47% | — |
#14
Prev: #—
|
4.5 |
—
|
305,000 | — |
NEW
|
305,000 | $9,848,450 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
IVA
INVENTIVA SA
|
Healthcare | 2.22% | 2.86% |
#15
6
Prev: #9
|
1.4 |
—
|
-35,000 | -1.4% |
P
S
|
2,400,000 | $8,856,000 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
IRON
CALL
DISC MEDICINE I...
|
CALL Option | 2.21% | 0.68% |
#16
14
Prev: #30
|
3.9 |
—
|
104,500 | 348.3% |
P
S
|
134,500 | $8,804,370 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
COGT
CALL
COGENT BIOSCIEN...
|
CALL Option | 2.13% | — |
#17
Prev: #—
|
4.4 |
—
|
265,000 | — |
NEW
|
265,000 | $8,485,300 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AVTX
AVALO THERAPEUT...
|
Healthcare | 1.73% | — |
#18
Prev: #—
|
4.2 |
—
|
450,000 | — |
NEW
|
450,000 | $6,898,500 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ACRS
ACLARIS THERAPE...
|
Healthcare | 1.58% | — |
#19
Prev: #—
|
4.1 |
—
|
1,200,000 | — |
NEW
|
1,200,000 | $6,312,000 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
RZLT
CALL
REZOLUTE INC
|
CALL Option | 1.38% | 1.45% |
#20
2
Prev: #18
|
3.1 |
—
|
423,500 | 47.1% |
P
S
|
1,323,500 | $5,479,290 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ASMB
ASSEMBLY BIOSCI...
|
Healthcare | 1.33% | 1.36% |
#21
1
Prev: #20
|
3.0 |
—
|
65,000 | 40.6% |
P
S
|
225,000 | $5,285,250 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ADAG
ADAGENE INC
|
Healthcare | 1.30% | 1.63% |
#22
6
Prev: #16
|
3.0 |
—
|
366,618 | 29.3% |
P
S
|
1,616,618 | $5,173,178 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
N/A
CRESCENT BIOPHA...
|
|
Unknown | 1.28% | — |
#23
Prev: #—
|
4.0 |
—
|
350,000 | — |
NEW
|
350,000 | $5,106,500 | — | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
YARW
YARROW BIOSCIEN...
|
Healthcare | 1.27% | — |
#24
Prev: #—
|
4.0 |
—
|
225,000 | — |
NEW
|
225,000 | $5,067,000 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ZURA
ZURA BIO LTD
|
Healthcare | 1.25% | — |
#25
Prev: #—
|
4.0 |
—
|
1,200,000 | — |
NEW
|
1,200,000 | $4,992,000 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
N/A
TCGX ACQUISITIO...
|
|
Unknown | 1.16% | — |
#26
Prev: #—
|
4.0 |
—
|
370,220 | — |
NEW
|
370,220 | $4,631,452 | — | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
CTNM
CONTINEUM THERA...
|
Healthcare | 1.09% | 1.32% |
#27
4
Prev: #23
|
2.9 |
—
|
63,570 | 24.4% |
P
S
|
323,570 | $4,342,309 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AVBP
CALL
ARRIVENT BIOPHA...
|
CALL Option | 1.08% | 1.97% |
#28
16
Prev: #12
|
0.4 |
—
|
-40,500 | -22.1% |
P
S
|
142,500 | $4,314,900 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
IKT
INHIBIKASE THER...
|
Healthcare | 1.03% | 1.89% |
#29
14
Prev: #15
|
0.4 |
—
|
-1,000,000 | -33.3% |
P
S
|
2,000,000 | $4,110,000 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
PALI
PALISADE BIO IN...
|
Healthcare | 1.02% | 1.95% |
#30
17
Prev: #13
|
1.4 |
—
|
no change | no change |
P
S
|
3,000,000 | $4,050,000 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
TNGX
TANGO THERAPEUT...
|
Healthcare | 0.94% | — |
#31
Prev: #—
|
3.9 |
—
|
150,000 | — |
NEW
|
150,000 | $3,742,500 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
JANX
JANUX THERAPEUT...
|
Healthcare | 0.93% | — |
#32
Prev: #—
|
3.9 |
—
|
215,000 | — |
NEW
|
215,000 | $3,715,200 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SVRA
SAVARA INC
|
Healthcare | 0.87% | — |
#33
Prev: #—
|
3.8 |
—
|
675,000 | — |
NEW
|
675,000 | $3,483,000 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CTNM
CALL
CONTINEUM THERA...
|
CALL Option | 0.76% | — |
#34
Prev: #—
|
3.8 |
—
|
225,000 | — |
NEW
|
225,000 | $3,019,500 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
N/A
QUINCE THERAPEU...
|
|
Unknown | 0.70% | 0.23% |
#35
3
Prev: #38
|
3.3 |
—
|
49,625 | 122.9% |
P
S
|
90,000 | $2,790,900 | — | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
N/A
JATT III ACQUIS...
|
|
Unknown | 0.69% | — |
#36
Prev: #—
|
3.8 |
—
|
250,000 | — |
NEW
|
250,000 | $2,755,000 | — | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
SCYX
SCYNEXIS INC
|
Healthcare | 0.64% | 0.96% |
#37
9
Prev: #28
|
0.3 |
—
|
-241,839 | -32.0% |
P
S
|
515,045 | $2,544,322 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SLN
CALL
SILENCE THERAPE...
|
CALL Option | 0.49% | — |
#38
Prev: #—
|
3.7 |
—
|
180,000 | — |
NEW
|
180,000 | $1,967,400 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ALXO
ALX ONCOLOGY HL...
|
Healthcare | 0.49% | — |
#39
Prev: #—
|
3.7 |
—
|
1,400,000 | — |
NEW
|
1,400,000 | $1,946,000 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
LPCN
LIPOCINE INC NE...
|
Healthcare | 0.45% | 0.64% |
#40
8
Prev: #32
|
1.2 |
—
|
no change | no change |
P
S
|
810,000 | $1,782,000 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
BIOA
CALL
BIOAGE LABS INC
|
CALL Option | 0.44% | 1.90% |
#41
27
Prev: #14
|
1.2 |
—
|
no change | no change |
P
S
|
250,000 | $1,772,500 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
PEPG
PEPGEN INC
|
Healthcare | 0.36% | — |
#42
Prev: #—
|
3.6 |
—
|
600,000 | — |
NEW
|
600,000 | $1,452,000 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CCCC
CALL
C4 THERAPEUTICS...
|
CALL Option | 0.33% | 0.58% |
#43
9
Prev: #34
|
1.1 |
—
|
no change | no change |
P
S
|
400,000 | $1,332,000 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
N/A
JATT II ACQUISI...
|
|
Unknown | 0.18% | — |
#44
Prev: #—
|
3.6 |
—
|
65,000 | — |
NEW
|
65,000 | $730,925 | — | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
ZNTL
CALL
ZENTALIS PHARMA...
|
CALL Option | 0.07% | 0.64% |
#45
12
Prev: #33
|
0.0 |
—
|
-326,000 | -76.5% |
P
S
|
100,000 | $277,000 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
NXTC
NEXTCURE INC
|
Healthcare | 0.00% | 0.03% |
Sold All 😨
(Was: #43) |
0.0 |
—
|
-64,464 | -100.0% |
CLOSED
|
— | $— | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
NMRA
NEUMORA THERAPE...
|
Healthcare | 0.00% | 0.05% |
Sold All 😨
(Was: #42) |
0.0 |
—
|
-100,000 | -100.0% |
CLOSED
|
— | $— | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
INM
INMED PHARMACEU...
|
Healthcare | 0.00% | 0.16% |
Sold All 😨
(Was: #41) |
0.0 |
—
|
-325,000 | -100.0% |
CLOSED
|
— | $— | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
KTTA
PASITHEA THERAP...
|
Healthcare | 0.00% | 0.16% |
Sold All 😨
(Was: #40) |
0.0 |
—
|
-1,000,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
NVCT
CALL
NUVECTIS PHARMA...
|
CALL Option | 0.00% | 0.22% |
Sold All 😨
(Was: #39) |
0.0 |
—
|
-38,700 | -100.0% |
CLOSED
|
— | $— | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 |
Showing 1-50 of 64 holdings